Proteasome Inhibitors and Bone Disease

Roodman, 2004, Pathogenesis of myeloma bone disease, Blood Cells Mol Dis, 32, 290, 10.1016/j.bcmd.2004.01.001 Giuliani, 2001, Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment, Blood, 98, 3527, 10.1182/blood.V98.13.3527 Pearse, 2001, Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression, Proc Natl Acad Sci U S A, 98, 11581, 10.1073/pnas.201394498 Bataille, 1989, Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease, J Clin Oncol, 7, 1909, 10.1200/JCO.1989.7.12.1909 Richardson, 2006, Bortezomib: proteasome inhibition as an effective anticancer therapy, Annu Rev Med, 57, 33, 10.1146/annurev.med.57.042905.122625 Terpos, 2007, Myeloma bone disease and proteasome inhibition therapies, Blood, 110, 1098, 10.1182/blood-2007-03-067710 Zangari, 2005, Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma, Br J Haematol, 131, 71, 10.1111/j.1365-2141.2005.05733.x Garrett, 2003, Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro, J Clin Invest, 111, 1771, 10.1172/JCI16198 Giuliani, 2007, The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients, Blood, 110, 334, 10.1182/blood-2006-11-059188 Mukherjee, 2008, Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice, J Clin Invest, 118, 491 Qiang, 2009, Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling, Blood, 113, 4319, 10.1182/blood-2008-08-174300 Oyajobi, 2007, Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease, Br J Haematol, 139, 434, 10.1111/j.1365-2141.2007.06829.x Pennisi, 2009, The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo, Am J Hematol, 84, 6, 10.1002/ajh.21310 Heider, 2006, Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment, Eur J Haematol, 77, 233, 10.1111/j.1600-0609.2006.00692.x Shimazaki, 2005, High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation, Leukemia, 19, 1102, 10.1038/sj.leu.2403758 Zangari, 2006, Response to bortezomib and activation of osteoblasts in multiple myeloma, Clin Lymphoma Myeloma, 7, 109, 10.3816/CLM.2006.n.047 Lund, 2010, First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro, Eur J Haematol, 85, 290, 10.1111/j.1600-0609.2010.01485.x Zangari, 2011, Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients, Eur J Haematol, 86, 484, 10.1111/j.1600-0609.2011.01602.x Silvestris, 2004, Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells, Br J Haematol, 126, 475, 10.1111/j.1365-2141.2004.05084.x Silvestris, 2003, Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease, Br J Haematol, 122, 39, 10.1046/j.1365-2141.2003.04374.x Prockop, 1997, Marrow stromal cells as stem cells for nonhematopoietic tissues, Science, 276, 71, 10.1126/science.276.5309.71 Barille, 1995, Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin, Blood, 86, 3151, 10.1182/blood.V86.8.3151.3151 Giuliani, 2005, Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation, Blood, 106, 2472, 10.1182/blood-2004-12-4986 Evans, 1992, Myeloma affects both the growth and function of human osteoblast-like cells, Clin Exp Metastasis, 10, 33, 10.1007/BF00163574 Krishnan, 2006, Regulation of bone mass by Wnt signaling, J Clin Invest, 116, 1202, 10.1172/JCI28551 Ducy, 1997, Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation, Cell, 89, 747, 10.1016/S0092-8674(00)80257-3 Qiang, 2003, Wnt signaling in B-cell neoplasia, Oncogene, 22, 1536, 10.1038/sj.onc.1206239 Qiang, 2005, Wnts induce migration and invasion of myeloma plasma cells, Blood, 106, 1786, 10.1182/blood-2005-01-0049 Aberle, 1997, beta-catenin is a target for the ubiquitin-proteasome pathway, EMBO J, 16, 3797, 10.1093/emboj/16.13.3797 Kisselev, 2001, Proteasome inhibitors: from research tools to drug candidates, Chem Biol, 8, 739, 10.1016/S1074-5521(01)00056-4 Day, 2005, Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis, Dev Cell, 8, 739, 10.1016/j.devcel.2005.03.016 Qiang, 2010, Wnt signaling pathways in multiple myeloma (chapter 2), 51 Heider, 2009, Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment, Eur J Haematol, 82, 31, 10.1111/j.1600-0609.2008.01164.x Kaiser, 2008, Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma, Eur J Haematol, 80, 490, 10.1111/j.1600-0609.2008.01065.x Pinzone, 2009, The role of Dickkopf-1 in bone development, homeostasis, and disease, Blood, 113, 517, 10.1182/blood-2008-03-145169 Politou, 2006, Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation, Int J Cancer, 119, 1728, 10.1002/ijc.22033 Tian, 2003, The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma, N Engl J Med, 349, 2483, 10.1056/NEJMoa030847 Qiang, 2008, Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma, Bone, 42, 669, 10.1016/j.bone.2007.12.006 Qiang, 2008, Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth, Blood, 112, 374, 10.1182/blood-2007-10-120253 Yaccoby, 2007, Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo, Blood, 109, 2106, 10.1182/blood-2006-09-047712 Edwards, 2008, Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo, Blood, 111, 2833, 10.1182/blood-2007-03-077685 Ng, 2011, Bone microstructural changes revealed by HRpQCT imaging and elevated DKK1 and MIP-1alpha levels in patients with monoclonal gammopathy of undetermined significance, Blood, 118, 6529, 10.1182/blood-2011-04-351437 Oshima, 2005, Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2, Blood, 106, 3160, 10.1182/blood-2004-12-4940 Qiang, 2008, Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma, Blood, 112, 196, 10.1182/blood-2008-01-132134 Terpos, 2006, Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma, Br J Haematol, 135, 688, 10.1111/j.1365-2141.2006.06356.x Komori, 2002, Runx2, a multifunctional transcription factor in skeletal development, J Cell Biochem, 87, 1, 10.1002/jcb.10276 Zhao, 2003, E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation, J Biol Chem, 278, 27939, 10.1074/jbc.M304132200 Shui, 2003, Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells, J Bone Miner Res, 18, 213, 10.1359/jbmr.2003.18.2.213 Giuliani, 2006, Multiple myeloma bone disease: pathophysiology of osteoblast inhibition, Blood, 108, 3992, 10.1182/blood-2006-05-026112 Sezer, 2003, RANK ligand and osteoprotegerin in myeloma bone disease, Blood, 101, 2094, 10.1182/blood-2002-09-2684 Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3 O'Brien, 2010, Control of RANKL gene expression, Bone, 46, 911, 10.1016/j.bone.2009.08.050 Terpos, 2003, Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index, Blood, 102, 1064, 10.1182/blood-2003-02-0380 Zavrski, 2005, Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function, Biochem Biophys Res Commun, 333, 200, 10.1016/j.bbrc.2005.05.098 Ang, 2009, Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades, J Cell Physiol, 220, 450, 10.1002/jcp.21787 von Metzler, 2007, Bortezomib inhibits human osteoclastogenesis, Leukemia, 21, 2025, 10.1038/sj.leu.2404806 Breitkreutz, 2008, Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma, Leukemia, 22, 1925, 10.1038/leu.2008.174 Boissy, 2008, Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions, Leuk Res, 32, 1661, 10.1016/j.leukres.2008.02.019 Terpos, 2008, The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis, Leukemia, 22, 2247, 10.1038/leu.2008.235 Uy, 2007, Bortezomib inhibits osteoclast activity in patients with multiple myeloma, Clin Lymphoma Myeloma, 7, 587, 10.3816/CLM.2007.n.045 Glass, 2005, Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation, Dev Cell, 8, 751, 10.1016/j.devcel.2005.02.017 Holmen, 2005, Essential role of beta-catenin in postnatal bone acquisition, J Biol Chem, 280, 21162, 10.1074/jbc.M501900200 Spencer, 2006, Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro, J Cell Sci, 119, 1283, 10.1242/jcs.02883 Willert, 2002, A transcriptional response to Wnt protein in human embryonic carcinoma cells, BMC Dev Biol, 2, 8, 10.1186/1471-213X-2-8 Qiang, 2010, Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma, Br J Haematol, 148, 726, 10.1111/j.1365-2141.2009.08009.x Hongming, 2009, Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6, Leuk Res, 33, 115, 10.1016/j.leukres.2008.07.028 Meller, 2006, Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons, J Biol Chem, 281, 7429, 10.1074/jbc.M512138200 Akiyama, 2003, Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim, EMBO J, 22, 6653, 10.1093/emboj/cdg635 Roccaro, 2006, Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells, Cancer Res, 66, 184, 10.1158/0008-5472.CAN-05-1195